Captopril
- Generic Name
- Captopril
- Drug Type
- Small Molecule
- Chemical Formula
- C9H15NO3S
- CAS Number
- 62571-86-2
- Unique Ingredient Identifier
- 9G64RSX1XD
- Background
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
- Indication
For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
- Associated Conditions
- Aldosteronism, Anatomic renal artery stenosis, Congestive Heart Failure (CHF), Diabetic Nephropathy, Heart Failure, Hypertension, Hypertensive crisis, Non-STEMI Acute Coronary Syndrome, Raynaud's Phenomenon, Ejection fraction of 40% or less Left ventricular dysfunction
Effect of Captopril on GLS in Duchenne Myodystrophy
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 20
- Registration Number
- NCT06485661
- Locations
- 🇪🇬
Ain Shams university, Cairo, Egypt
A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06292091
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Alpha-lipoic Acid in Diabetic Nephropathy
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: Thioctic Acid 333 MG Oral Capsule
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 30
- Registration Number
- NCT06253429
- Locations
- 🇪🇬
Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt
NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Natural Wellness Egypt
- Target Recruit Count
- 286
- Registration Number
- NCT06141200
Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
- Conditions
- Congenital Mitral Insufficiency
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 164
- Registration Number
- NCT06039592
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Study of Drug Therapy for Pediatric Heart Failure
- Conditions
- Heart Failure Congenital
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 200
- Registration Number
- NCT06039540
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation
- Conditions
- Congenital Mitral Insufficiency
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 122
- Registration Number
- NCT06037434
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 200
- Registration Number
- NCT05442463
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
- Conditions
- Non-hodgkin LymphomaHodgkin Lymphoma
- Interventions
- Drug: DOC Group BDrug: Bv-NVD-R, Cycle 1-2Drug: DOC Group CDrug: Bv-AVD-RDrug: Bv-NVD-R, Cycle 1-4 RERDrug: Pv-COMRAD 1 and 2 Group BDrug: Bv-NVD-R, Cycle 1-4 SERDrug: MAD CPR 1 and 2Drug: Pv-R-CYM 1 and 2 Group BDrug: Bv-NAVD-R, Cycle 1-2Drug: Pv-R CYVE 1 and 2Drug: Pv-R CYVE-MTX 1 and 2Drug: Pv-Cytarabine/etoposideRadiation: Involved Site Radiation Therapy
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 80
- Registration Number
- NCT05253495
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸University of Flordia, Gainesville, Florida, United States
Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT04878315
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.